Retropharyngeal Neck Dissection




Introduction


The retropharyngeal lymph nodes (RPLNs) are a small chain of lymph nodes located in the retropharyngeal space (RP) where they are divided into the medial and lateral groups. The boundaries of the RP are the carotid sheath laterally, skull base superiorly, prevertebral fascia posteriorly, and the pharynx anteriorly, and inferiorly, the RP is in continuity with the posterior mediastinum. The medial group of nodes are usually ill-defined and often absent in adults, thus not having a significant role in RPLN metastases. The lateral RPLN, which lies superior to the sympathetic ganglion at the level of C1, can harbor metastases from a variety of cancers; oropharyngeal cancer being the most common. There may be one to three nodes that are often difficult to identify in the absence of metastatic involvement. Typically, the lateral RPLNs are usually smaller than 4 to 4.5 mm in the greatest diameter of their shortest axis, where 6 to 10 mm has been described as the pathologic threshold for RPLNs.


Rouviere, in 1938, first mapped lymphatic drainage of the oropharynx and characterized the spread of oropharyngeal carcinomas to the RP. RPLN positivity in all oropharyngeal squamous cell carcinomas (OPSCC) has been found to be 10% to 27%, using a variety of imaging modalities. Additionally, RPLN involvement in OPSCC is an important prognostic factor and has been shown that there is an increased risk for regional recurrence (45% vs. 10%) and reduced rates of disease-specific survival (38% vs. 58%). RPLN metastases are more common from the soft palate and posterior pharynx, but they can occur from any subsite within the oropharynx. Due to the incidence of metastases, the RPLNs are routinely targeted during radiation therapy for OPSCC. Currently, when the lateral lymphatics of the neck are dissected in a conventional selective neck dissection, the RPLNs are not routinely dissected. With increasing use of transoral surgery (TOS) as a primary treatment modality for OPSCC, dissection of the RPLN during cervical lymphadenectomy becomes more important, especially in cases where no adjuvant treatment is recommended.




Key Operative Learning Points





  • Approach can be transcervical or transoral




    • Transcervical approach preferred if a concurrent neck dissection is being performed




  • Avoid injury to the sympathetic chain that is located lateral to the RPLN and can often be mistaken for lymphadenopathy



  • A positive positron emission tomography (PET)/computed tomography (CT) of the RPLN has an excellent PPV and suggests that the RPLN needs to be addressed when primary or recurrent squamous cell carcinomas (SCC) are present.





Preoperative Period


The keys to deciding when to perform the surgery in the primary setting are: (1) to ascertain the risk of RPLN metastases based on the oropharyngeal cancer subsite and nodal cancer burden and (2) decide whether primary surgical treatment will be employed. If preoperative imaging suggests metastasis in the RPLN and a neck dissection is being performed, the RPLN can be safely dissected in this situation. If the RPLN is negative on PET/CT and another imaging modality (CT or magnetic resonance imaging [MRI]), then the RPLN can either be ignored or treated electively with radiation therapy, depending on the TNM staging and subsite ( Fig. 68.1 ). In the setting of lymph node metastasis persistence or recurrence after chemoradiation, PET/CT has demonstrated adequate accuracy at predicting RPLN disease and can be used to guide whether the RPLNs need to be addressed during a salvage-neck dissection. As with all head and neck cancers, I advocate for presenting the patient to a multidisciplinary tumor board and considering various factors, for example, the patient’s comorbidities, preferences, and social situation prior to proceeding with primary treatment.




Fig. 68.1


Depiction of the transcervical approach to the retropharyngeal lymph nodes following a selective neck dissection. ICA, Internal carotid artery. IJV, Internal Jugular Vein.


The RPLN can be approached by using either a transcervical or transoral technique. I suggest a transcervical approach in the primary setting when performed in conjunction with an elective neck dissection. The technique for the transcervical approach, as outlined below, has been demonstrated to be a safe and reliable method of RPLN sampling during primary surgical management. For therapeutic removal of a metastatic RPLN, both the transcervical and transoral techniques can be used. If a concurrent neck dissection is being performed, I prefer using the transcervical approach to avoid violating the pharynx and creating a potential salivary fistula. If, however, the RPLN is the only node being removed (i.e., in the case of a previously dissected neck with only a RPLN positive node or a solitary papillary thyroid cancer metastasis), then a transoral approach can be considered to avoid an external incision based on the familiarity of the surgeon with the anatomy and techniques.


If primary surgical therapy is being considered for the oropharyngeal cancer, informed consent must include the usual potential morbidity associated with the primary resection of the cancer and the selective neck dissection. In addition to these risks, the RPLN dissection through a transcervical approach increases the risk of a salivary fistula due to the close proximity to the pharynx. Also, the dissection of the RPLN can include potential damage to cranial nerve (CN) IX and the sympathetic chain, which can increase the risk of aspiration and result in Horner’s syndrome, respectively. If the transoral approach is performed in isolation, there is minimal risk of a salivary fistula but the incidences of postoperative aspiration, Horner’s syndrome, and damage to major vessels are likely increased due to the limited exposure and technical difficulties associated with this approach.


History




  • 1.

    History of present illness



    • a.

      Risk factors: smoking, alcohol, Human papillomavirus (HPV) infection


    • b.

      Weight loss, nutritional status


    • c.

      New onset of pain in the pharynx or otalgia


    • d.

      Dysphagia/odynophagia


    • e.

      Neurologic deficits


    • f.

      Voice changes


    • g.

      Presence of masses or lesions in the throat or neck



  • 2.

    Past medical history



    • a.

      Previous squamous cell carcinomas or thyroid cancer


    • b.

      Previous radiation to the head and neck


    • c.

      Previous surgery or trauma to the neck or pharynx



  • 3.

    Prior treatment of oropharynx or neck



    • a.

      Previous (chemo)radiation for oral/oropharyngeal cancer


    • b.

      Prior surgery for metastatic thyroid cancer



  • 4.

    Medical illness



    • a.

      Cardiopulmonary disease


    • b.

      Alcoholism, risk of perioperative alcohol withdrawal syndrome and substance abuse


    • c.

      Sexual history for risk of HPV exposure



  • 5.

    Medications



    • a.

      Anticoagulants


    • b.

      Allergies to antibiotics



  • 6.

    Mental and social status



    • a.

      Ability to give informed consent




Physical Examination




  • 1.

    Oropharyngeal cancer



    • a.

      Determine primary site and tumor extent (if present)



      • 1)

        Tonsil



        • a)

          Extension to soft palate, base of tongue (BOT), and posterior oropharynx


        • b)

          Invasion of the mandible



      • 2)

        Palate



        • a)

          Extension into the mucosa on the nasal side


        • b)

          Involvement of the hard palate or other oropharyngeal structures



      • 3)

        Posterior oropharynx



        • a)

          Extension into nasopharynx


        • b)

          Direct extension to the RPLN space



      • 4)

        BOT



        • a)

          Extension to contralateral BOT


        • b)

          Involvement of other oropharyngeal structures or mandible



      • 5)

        Invasion of major nerves



        • a)

          Lingual nerve (loss of sensation of anterior tongue and floor of mouth)


        • b)

          Inferior alveolar nerve (loss of sensory function of mental nerve)


        • c)

          Hypoglossal nerve (deviation of tongue)


        • d)

          Glossopharyngeal nerve (lack of palate sensation, may be difficult to assess)





  • 2.

    Assessment of nodal extension



    • a.

      Oropharyngeal examination and palpation (if tolerated)



  • 3.

    Cervical lymph node metastasis



    • a.

      Palpate the neck for the presence of cervical metastases.


    • b.

      Examine the neck for previous surgery and scars that may affect surgical planning.



  • 4.

    Examine the oral cavity, pharynx, and larynx for synchronous primaries.


  • 5.

    Thyroid



    • a.

      If there is a history of thyroid cancer and the RPLN appears to be a thyroid metastasis



  • 6.

    Fiberoptic laryngoscopy



    • a.

      Particular attention to superior and inferior extent of primary cancer and RPLN



  • 7.

    General health



    • a.

      Nutrition


    • b.

      Cardiovascular


    • c.

      Respiratory


    • d.

      Mental




Imaging




  • 1.

    Chest radiograph



    • a.

      Metastases


    • b.

      Synchronous lung cancer


    • c.

      Pulmonary and cardiac status



  • 2.

    CT scan of the neck with contrast



    • a.

      Important to assess the relationship of the node(s) with the prevertebral fascia and carotid artery


    • b.

      Assess the extent of the primary cancer.



  • 3.

    PET/CT



    • a.

      Data suggest it is an extremely sensitive modality to assessing for recurrent disease and RPLN metastasis.


    • b.

      Provides information regarding distant metastasis



  • 4.

    Thyroid scan



    • a.

      Required only if thyroid metastasis suspected


    • b.

      Can provide information regarding adjuvant treatment with I131, in addition to information on other metastatic sites




Indications





  • Salvage following previous (chemo)radiation with PET/CT demonstrating persistent cancer



  • Presence of a metastatic node from a primary cancer in the thyroid



  • Primary surgical treatment of an oropharyngeal cancer with advanced lymph node metastasis (N2b or higher)



Contraindications




  • 1.

    Patient factors



    • a.

      Medically unfit


    • b.

      Poor nutritional status


    • c.

      Inability to give informed consent


    • d.

      Severe trismus



  • 2.

    Tumor factors



    • a.

      Early stage oropharyngeal SCC in the primary surgical setting


    • b.

      Distant metastases


    • c.

      Negative PET/CT scan for RPLN disease


    • d.

      Unresectable cancer with gross fixation to the prevertebral musculature



  • 3.

    Surgical factors



    • a.

      Inadequate expertise with resection via a transcervical approach




Preoperative Preparation




  • 1.

    Evaluations by



    • a.

      Oncologic Surgeon


    • b.

      Radiation and Medical Oncologist


    • c.

      Speech and swallowing therapist


    • d.

      Anesthesiology


    • e.

      Tumor board presentation



  • 2.

    Postoperative care planning


  • 3.

    Discontinue antiplatelet drugs if possible.


Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Apr 3, 2019 | Posted by in OTOLARYNGOLOGY | Comments Off on Retropharyngeal Neck Dissection

Full access? Get Clinical Tree

Get Clinical Tree app for offline access